Close

Anti-VEGFR2 TriCAR (Bevacizumab) (28ζ), pCDCAR1 (TriCAR-Z443)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The anti-VEGFR2 TriCAR is a novel chimeric antigen receptor (CAR) constructed for the engineering of T cells to target Human VEGFR2.More specifically, the TriCAR is a CAR-T with unique TriTE (Tri-functional T cell Engager) construct. In general, TriTE is a fusion protein with unique functions including T cell engagement, T cell stimulation, and check point blocking. It consists of five components, including R1(antigen binding domain), R2 (anti-CD3, here refer to the CD28/4-1BB-CD3ζ intracellular constimulatory domain), R3 & R4(IL15 binding domain), and R5 (PD1 for binding to PD-L1). Therefore, the TriCAR contains an anti-antigen scFv, a PD-L1 blocker, and a cytokine complex, enabling the TriCAR/SILK to simultaneously targeting the antigen-specific cancer cells, blocking the inhibitory PD-L1 signal and stimulating innate T/NK cell activation and expansion, thus make it a tri-functional CAR (Tri-CAR).

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • VEGFR2
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Melanoma
  • Generation
  • Fourth
  • Vector Name
  • pCDCAR1
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-Sushi Domain-CD28-CD3ζ-PP2A-IL15-Anti-PD-L1
  • Discription of Signaling Cassetes
  • TriCAR is a CAR-T with unique TriTE (Tri-functional T cell Engager) construct. TriTE is a fusion protein with unique functions including T cell engagement, T cell stimulation, and check point blocking. It consists of five components, including R1(antigen binding domain), R2 (CD28/4-1BB-CD3ζ intracellular constimulatory domain), R3 & R4(IL15 binding domain), and R5 (PD1 for binding to PD-L1). The R1 component binds to a specific cancer antigen on T cells , and and at the same time, the IL15 and PD1 (R4&R5) domains improve the in-tumor micro-environment for solid tumor immunotherapies.

Target

  • Clone
  • Bevacizumab
  • Target Species
  • Human
  • Gene Name
  • kinase insert domain receptor
  • Synonyms
  • FLK1; CD309; VEGFR; VEGFR2

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-VEGFR2 TriCAR (Bevacizumab) (scFv-Sushi Domain-CD28-CD3ζ-PP2A-IL15-Anti-PD-L1), pCDCAR1 (TriCAR-Z443). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.